Pharmaceutical company Eli Lilly and Company says it will go ahead and produce a groundbreaking imaging chemical designed to help screen for Alzheimer's disease.

The announcement came despite the Centers for Medicare and Mecaid Service's ruling that the agency would not cover the chemical, which highlights brain plaque in medical imaging scans.

Medicare officials say that more trials are needed to prove that the tool works.

There are currently no treatments for Alzheimer's disease.

Read or Share this story: